A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project

Levis, Mario; Luca, V. De; Bartoncini, Sara; Botto, Barbara; Giorgi, Mauro; Chiappella, Annalisa; Ferrero, Simone; Fava, Antonella; Cavallo, Federica; Caracciolo, Daniele; Vicentini, Silvia; Gastino, A.; Furfaro, Gabriella; Priolo, G; Pregno, Patrizia; Filippi, Andrea Riccardo; Vitolo, Umberto; Orsucci, Lorella; Ricardi, Umberto

doi:10.1016/j.ijrobp.2018.06.230

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A GLS reduction of >15% from baseline is considered an early marker of subclinical cardiac toxicity 16 and may suggest a timely start of cardioprotective treatment, to prevent the progression to overt systolic dysfunction. Interim results of the ongoing CARDIOCARE project (NCT 03480087) have showed a significant correlation of the acute deterioration in average GLS with the dose of anthracyclines and the dose of radiation received by the left ventricle in adult lymphoma patients 69 .…”

Section: Follow-up and Early Detectionmentioning

confidence: 99%

An integrated approach to cardioprotection in lymphomas

Maraldo¹,

Levis²,

Andreis³

et al. 2022

The Lancet Haematology

View full text Add to dashboard Cite

Section: Follow-up and Early Detectionmentioning

confidence: 99%

An integrated approach to cardioprotection in lymphomas

Maraldo¹,

Levis²,

Andreis³

et al. 2022

The Lancet Haematology

View full text Add to dashboard Cite

“…The ongoing CARDIOCARE project (Clinical Trial identifier: NCT03480087) has firstly shown a significant impairment of left ventricular systolic function, evaluated with global longitudinal strain, in patients receiving an MHD > 5 Gy and a mean left ventricular dose > 2 Gy [67], thus suggesting an indicative dose limit for ventricular dysfunction.…”

Section: Heartmentioning

confidence: 99%

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin’s lymphoma involving the mediastinum

et al. 2020

View full text Add to dashboard Cite

Aim: Advances in therapy have resulted in improved cure rates and an increasing number of long-term Hodgkin's lymphoma (HL) survivors. However, radiotherapy (RT)-related late effects are still a significant issue, particularly for younger patients with mediastinal disease (secondary cancers, heart diseases). In many Centers, technological evolution has substantially changed RT planning and delivery. This consensus document aims to analyze the current knowledge of Intensity-Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) for mediastinal HL and formulate practical recommendations based on scientific evidence and expert opinions. Methods: A dedicated working group was set up within the Fondazione Italiana Linfomi (FIL) Radiotherapy Committee in May 2018. After a first meeting, the group adopted a dedicated platform to share retrieved articles and other material. Two group coordinators redacted a first document draft, that was further discussed and finalized in two subsequent meetings. Topics of interest were: 1) Published data comparing 3D-conformal radiotherapy (3D-CRT) and IMRT 2) dose objectives for the organs at risk 3) IGRT protocols and motion management.

show abstract